Adicet reports third quarter 2020 financial results and provides business update

Menlo park, calif. and boston, nov. 05, 2020 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing first-in-class allogeneic gamma delta t cell therapies for cancer and other diseases, today reported financial results for the third quarter ended september 30, 2020.

ACET Ratings Summary

ACET Quant Ranking